Nuo Therapeutics Company Profile (OTCMKTS:CMXI)

About Nuo Therapeutics (OTCMKTS:CMXI)

Nuo Therapeutics logoNuo Therapeutics, Inc., formerly Cytomedix, Inc., is a regenerative therapies company developing and marketing products within the United States and internationally through its strategic partners. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's commercial offerings are centered on its point of care platform technologies for the separation of blood and bone marrow to produce platelet based therapies or cell concentrates. It is promoting two distinct platelet rich plasma (PRP) technologies: the Aurix System for wound care, and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics and cardiovascular markets. The Company is focused on developing product candidates utilizing the Bright Cell technology platform, owned by its subsidiary, Aldagen, Inc.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CMXI
  • CUSIP: N/A
  • Web:
  • Trailing P/E Ratio:
  • P/E Growth:
  • Dividend Yield: 1.0%
  • Net Margins: -637.52%
  • Return on Equity: -430.66%
  • Return on Assets: -169.06%

Frequently Asked Questions for Nuo Therapeutics (OTCMKTS:CMXI)

What is Nuo Therapeutics' stock symbol?

Nuo Therapeutics trades on the OTCMKTS under the ticker symbol "CMXI."

Who are some of Nuo Therapeutics' key competitors?

Who are Nuo Therapeutics' key executives?

Nuo Therapeutics' management team includes the folowing people:

  • David Emerson Jorden CPA, Chief Executive Officer, Chief Financial Officer, Director
  • Peter A. Clausen Ph.D., Chief Science Officer
  • Shaun C Martin, Chief Restructuring Officer
  • Lawrence Atinsky, Director
  • Paul D. Mintz M.D., Director
  • Lyle A. Hohnke Ph.D., Independent Director
  • Mark T. McLoughlin, Independent Director
  • C. Eric Winzer, Independent Director

How do I buy Nuo Therapeutics stock?

Shares of Nuo Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Nuo Therapeutics' stock price today?

One share of Nuo Therapeutics stock can currently be purchased for approximately $0.34.

MarketBeat Community Rating for Nuo Therapeutics (OTCMKTS CMXI)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  6 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  16
MarketBeat's community ratings are surveys of what our community members think about Nuo Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Nuo Therapeutics (OTCMKTS:CMXI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Nuo Therapeutics (OTCMKTS:CMXI)
Price Target History for Nuo Therapeutics (OTCMKTS:CMXI)
Analysts' Ratings History for Nuo Therapeutics (OTCMKTS:CMXI)
No equities research coverage for this company has been tracked by


Earnings History for Nuo Therapeutics (OTCMKTS:CMXI)
Earnings by Quarter for Nuo Therapeutics (OTCMKTS:CMXI)
Earnings History by Quarter for Nuo Therapeutics (OTCMKTS CMXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/22/2014($0.04)($0.05)ViewN/AView Earnings Details
4/2/2014($0.04)($0.05)ViewN/AView Earnings Details
11/12/2013Q3($0.04)($0.05)ViewListenView Earnings Details
3/18/20134Q12($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Nuo Therapeutics (OTCMKTS:CMXI)

No earnings estimates for this company have been tracked by


Dividend History for Nuo Therapeutics (OTCMKTS:CMXI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Nuo Therapeutics (OTCMKTS:CMXI)
Insider Trades by Quarter for Nuo Therapeutics (OTCMKTS:CMXI)
Insider Trades by Quarter for Nuo Therapeutics (OTCMKTS:CMXI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/6/2014Dean TozerInsiderBuy33,300$0.36$11,988.00View SEC Filing  
9/12/2014Dean TozerInsiderBuy40,000$0.45$18,000.00View SEC Filing  
8/29/2014Dean TozerInsiderBuy40,000$0.35$14,000.00View SEC Filing  
8/26/2014Steven A ShallcrossCFOBuy27,500$0.38$10,450.00View SEC Filing  
8/22/2014Dean TozerInsiderBuy38,700$0.38$14,706.00View SEC Filing  
8/20/2014Dean TozerInsiderBuy48,000$0.39$18,720.00View SEC Filing  
8/20/2014Martin P RosendaleCEOBuy25,000$0.40$10,000.00View SEC Filing  
8/20/2014Steven A ShallcrossCFOBuy52,000$0.39$20,280.00View SEC Filing  
5/21/2013David Emerson JordenDirectorBuy80,000$0.50$40,000.00View SEC Filing  
4/19/2013David Emerson JordenDirectorBuy50,000$0.51$25,500.00View SEC Filing  
4/9/2013David Emerson JordenDirectorBuy75,000$0.51$38,250.00View SEC Filing  
4/4/2013Martin P RosendaleCEOBuy17,231$0.52$8,960.12View SEC Filing  
2/27/2013David Emerson JordenDirectorBuy25,000$0.52$13,000.00View SEC Filing  
2/22/2013Aldagen Holdings, LlcInsiderBuy281,819$0.55$155,000.45View SEC Filing  
2/22/2013David Emerson JordenDirectorBuy50,000$0.53$26,500.00View SEC Filing  
2/22/2013Martin P RosendaleCEOBuy20,000$0.53$10,600.00View SEC Filing  
2/19/2013Guercio Joseph DelDirectorBuy509,091$0.55$280,000.05View SEC Filing  
9/14/2012David Emerson JordenDirectorBuy25,000$0.89$22,250.00View SEC Filing  
9/11/2012David Emerson JordenDirectorBuy8,333$0.95$7,916.35View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Nuo Therapeutics (OTCMKTS:CMXI)
Latest Headlines for Nuo Therapeutics (OTCMKTS:CMXI)
Loading headlines, please wait.



Nuo Therapeutics (CMXI) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.